---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-049136"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:05:48.224295+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Madrigal names Mardi Dier as CFO; Alex Howarth transitions to advisor; GC Brian Lynch to depart by May 31

## Summary
- Mardi Dier appointed SVP & CFO effective March 11, 2024; previously CFO of Acelyrin (IPO), Ultragenyx, Portola.
- Dier receives $550K base salary, 45% target bonus, and $6.7M equity grant (RSUs, options, PSUs) under 2023 Inducement Plan.
- Outgoing CFO Alex Howarth remains Senior Advisor to May 31; separation includes 12-month salary, target bonus, equity acceleration, health benefits.
- SVP & General Counsel Brian Lynch to depart by May 31; similar separation terms: 12-month salary, target bonus, equity acceleration, health benefits.
- No disagreements with accounting policies or internal controls related to either departure.

## SEC filing metadata
- accession: 0001193125-24-049136
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312524049136/0001193125-24-049136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312524049136/d757603d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-049136
- JSON: https://secwatch.observer/filing/0001193125-24-049136.json
- Plain text: https://secwatch.observer/filing/0001193125-24-049136.txt

## Key facts
- Executive change
  Mardi C. Dier was appointed as Senior Vice President and Chief Financial Officer at MADRIGAL PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Senior Vice President and Chief Financial Officer
  source text: On February 28, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mardi C. Dier as Senior Vice President and Chief Financial Officer of the Company, effective March 11, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312524049136/0001193125-24-049136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.